diagonal-therapeutics
(2)
Alex Lugovskoy and the education of a company builder
Before co-founding Diagonal Therapeutics, Alex Lugovskoy spent two decades learning how scientific organizations work. His career runs through physics, protein engineering, and the less glamorous business of helping people do difficult things together.
Alexey Lugovskoy
Alexey 'Alex' Lugovskoy is the co-founder and CEO of Diagonal Therapeutics, a Watertown/Cambridge, Massachusetts biotech building 'clustering' antibodies that switch cellular signaling back on rather than block it. A Harvard-trained biophysicist who left physics after deciding green leaves were more interesting than tau neutrinos, he spent two decades in antibody R&D at Biogen, Merrimack, Morphic, and Dragonfly before launching Diagonal in 2022. He has co-invented an FDA-approved cancer drug, authored more than 100 patents and papers, and edits the antibody journal mAbs. In January 2026 Diagonal closed an oversubscribed $125M Series B co-led by Sanofi Ventures and Janus Henderson to push its lead program, DIAG723, into human trials for hereditary hemorrhagic telangiectasia.